Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capadenoson for ventricular rate control in atrial fibrillation
2007-003619-30Phase 2Completed
- Sponsor
- Bayer
- Start
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of capadenoson in Atrial fibrillation (AFib), sponsored by Bayer. Primary endpoints: Change in 24-hour mean ventricular heart rate and Change in ventricular heart rate during exercise tolerance test. Started Oct 2007; status: completed.
02
Drugs
capadenoson
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2007-003619-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003619-30.